U.S. nursing home deaths reach lowest levels since pandemic began
Apr 05, 2022
Nursing home residents continue to be more vulnerable both because of their age and underlying medical conditions.
Plant-based recombinant COVID-19 vaccine found to be effective
May 04, 2022
Vaccine efficacy ranged from 69.5% against symptomatic infection to 78.8% against moderate-to-severe disease.
Medicare to provide free COVID-19 rapid tests
Feb 04, 2022
At-home tests will be available at pharmacies and other locations for clients with Medicare Part B outpatient benefit.
Cost-sharing waivers did not cover all COVID-19 hospital care in 2020
Oct 27, 2021
The researchers found that 71.2% of privately insured patients and 49.1% of Medicare Advantage patients had cost sharing for any hospitalization-related service, including those billed by clinicians.
U.S. insurers could spend millions for ivermectin Rx for COVID-19
Jan 20, 2022
Claims data for private insurance and Medicare Advantage plans show a spike in inappropriate ivermectin prescriptions for COVID-19.
Many U.S. adults report pandemic-related sleep disturbances
Jan 03, 2022
Overall, 56% of respondents have experienced “COVID-somnia” sleep disturbances; this number was slightly higher among younger people versus older adults.
Large increase seen in U.S. nursing home deaths in 2020
Jun 22, 2021
There was a 32% increase in deaths among Medicare patients in U.S. nursing homes last year, according to a new report from the Department of Health and Human Services.
Postacute COVID-19 syndrome may affect physical, cognitive function
Nov 02, 2021
Increased levels of fatigue and dyspnea, and decreased levels of physical activity, were reported; 63% showed at least mild cognitive impairment.
Single dose of AZD7442 effectively prevents COVID-19
Apr 22, 2022
A relative risk reduction of 82.8% was seen in symptomatic COVID-19 at extended follow-up of a median of six months.
Prior SARS-CoV-2 infection less protective against omicron variant
Feb 11, 2022
The effectiveness of previous infection in the prevention of reinfection was about 90% for the alpha, beta and delta variants and 56% for the omicron variant.